nodes	percent_of_prediction	percent_of_DWPC	metapath
Fesoterodine—ABCB1—Mitoxantrone—lymphatic system cancer	0.113	0.206	CbGbCtD
Fesoterodine—CYP3A4—Cytarabine—lymphatic system cancer	0.0985	0.18	CbGbCtD
Fesoterodine—CYP3A4—Teniposide—lymphatic system cancer	0.097	0.177	CbGbCtD
Fesoterodine—ABCB1—Vincristine—lymphatic system cancer	0.0779	0.142	CbGbCtD
Fesoterodine—CYP3A4—Mitoxantrone—lymphatic system cancer	0.0679	0.124	CbGbCtD
Fesoterodine—ABCB1—Methotrexate—lymphatic system cancer	0.0472	0.086	CbGbCtD
Fesoterodine—CYP3A4—Vincristine—lymphatic system cancer	0.0467	0.0851	CbGbCtD
Fesoterodine—Dry cough—Bleomycin—lymphatic system cancer	0.0405	0.0896	CcSEcCtD
Fesoterodine—Urinary hesitation—Fludarabine—lymphatic system cancer	0.0208	0.0461	CcSEcCtD
Fesoterodine—Dry cough—Methotrexate—lymphatic system cancer	0.0164	0.0362	CcSEcCtD
Fesoterodine—Obstructive airways disorder—Methotrexate—lymphatic system cancer	0.0111	0.0247	CcSEcCtD
Fesoterodine—Gamma-glutamyltransferase increased—Mitoxantrone—lymphatic system cancer	0.00617	0.0137	CcSEcCtD
Fesoterodine—Hepatic enzyme increased—Mitoxantrone—lymphatic system cancer	0.00537	0.0119	CcSEcCtD
Fesoterodine—Angina pectoris—Fludarabine—lymphatic system cancer	0.00522	0.0116	CcSEcCtD
Fesoterodine—Vertigo—Mechlorethamine—lymphatic system cancer	0.00517	0.0115	CcSEcCtD
Fesoterodine—Dysuria—Fludarabine—lymphatic system cancer	0.00501	0.0111	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Fludarabine—lymphatic system cancer	0.00498	0.011	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Mechlorethamine—lymphatic system cancer	0.00487	0.0108	CcSEcCtD
Fesoterodine—Infection—Mechlorethamine—lymphatic system cancer	0.00467	0.0103	CcSEcCtD
Fesoterodine—Urinary tract infection—Fludarabine—lymphatic system cancer	0.00464	0.0103	CcSEcCtD
Fesoterodine—Skin disorder—Mechlorethamine—lymphatic system cancer	0.00457	0.0101	CcSEcCtD
Fesoterodine—Face oedema—Carmustine—lymphatic system cancer	0.00383	0.00848	CcSEcCtD
Fesoterodine—Chest pain—Teniposide—lymphatic system cancer	0.00361	0.008	CcSEcCtD
Fesoterodine—Urinary retention—Vincristine—lymphatic system cancer	0.0036	0.00797	CcSEcCtD
Fesoterodine—Confusional state—Teniposide—lymphatic system cancer	0.00349	0.00774	CcSEcCtD
Fesoterodine—Hypersensitivity—Mechlorethamine—lymphatic system cancer	0.00346	0.00767	CcSEcCtD
Fesoterodine—Infection—Teniposide—lymphatic system cancer	0.00344	0.00762	CcSEcCtD
Fesoterodine—Tachycardia—Teniposide—lymphatic system cancer	0.00338	0.00749	CcSEcCtD
Fesoterodine—Abdominal pain upper—Mitoxantrone—lymphatic system cancer	0.00337	0.00746	CcSEcCtD
Fesoterodine—Pruritus—Mechlorethamine—lymphatic system cancer	0.00333	0.00736	CcSEcCtD
Fesoterodine—Cough—Fludarabine—lymphatic system cancer	0.00326	0.00721	CcSEcCtD
Fesoterodine—Alanine aminotransferase increased—Mitoxantrone—lymphatic system cancer	0.00325	0.0072	CcSEcCtD
Fesoterodine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.00322	0.00712	CcSEcCtD
Fesoterodine—Confusional state—Fludarabine—lymphatic system cancer	0.00307	0.0068	CcSEcCtD
Fesoterodine—Dysuria—Vincristine—lymphatic system cancer	0.00306	0.00678	CcSEcCtD
Fesoterodine—Infection—Fludarabine—lymphatic system cancer	0.00303	0.0067	CcSEcCtD
Fesoterodine—Nervous system disorder—Fludarabine—lymphatic system cancer	0.00299	0.00661	CcSEcCtD
Fesoterodine—Urinary tract infection—Carmustine—lymphatic system cancer	0.00297	0.00658	CcSEcCtD
Fesoterodine—Rash—Mechlorethamine—lymphatic system cancer	0.00296	0.00656	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	0.00296	0.00656	CcSEcCtD
Fesoterodine—Dermatitis—Mechlorethamine—lymphatic system cancer	0.00296	0.00656	CcSEcCtD
Fesoterodine—Feeling abnormal—Teniposide—lymphatic system cancer	0.00286	0.00632	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Teniposide—lymphatic system cancer	0.00283	0.00627	CcSEcCtD
Fesoterodine—Nausea—Mechlorethamine—lymphatic system cancer	0.00279	0.00618	CcSEcCtD
Fesoterodine—Urinary tract infection—Mitoxantrone—lymphatic system cancer	0.00276	0.00612	CcSEcCtD
Fesoterodine—Urticaria—Teniposide—lymphatic system cancer	0.00275	0.0061	CcSEcCtD
Fesoterodine—Abdominal pain—Teniposide—lymphatic system cancer	0.00274	0.00607	CcSEcCtD
Fesoterodine—Oedema peripheral—Carmustine—lymphatic system cancer	0.0027	0.00598	CcSEcCtD
Fesoterodine—Dyspepsia—Fludarabine—lymphatic system cancer	0.00268	0.00594	CcSEcCtD
Fesoterodine—Hepatic enzyme increased—Methotrexate—lymphatic system cancer	0.00268	0.00592	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Fludarabine—lymphatic system cancer	0.00263	0.00582	CcSEcCtD
Fesoterodine—Fatigue—Fludarabine—lymphatic system cancer	0.00263	0.00581	CcSEcCtD
Fesoterodine—Constipation—Fludarabine—lymphatic system cancer	0.0026	0.00577	CcSEcCtD
Fesoterodine—Urinary tract disorder—Vincristine—lymphatic system cancer	0.00259	0.00573	CcSEcCtD
Fesoterodine—Urethral disorder—Vincristine—lymphatic system cancer	0.00257	0.00568	CcSEcCtD
Fesoterodine—Eye disorder—Carmustine—lymphatic system cancer	0.00256	0.00568	CcSEcCtD
Fesoterodine—Hypersensitivity—Teniposide—lymphatic system cancer	0.00255	0.00565	CcSEcCtD
Fesoterodine—Feeling abnormal—Fludarabine—lymphatic system cancer	0.00251	0.00556	CcSEcCtD
Fesoterodine—Asthenia—Teniposide—lymphatic system cancer	0.00249	0.00551	CcSEcCtD
Fesoterodine—Pruritus—Teniposide—lymphatic system cancer	0.00245	0.00543	CcSEcCtD
Fesoterodine—Cardiac disorder—Vincristine—lymphatic system cancer	0.00243	0.00538	CcSEcCtD
Fesoterodine—Mental disorder—Carmustine—lymphatic system cancer	0.0024	0.00532	CcSEcCtD
Fesoterodine—Cough—Bleomycin—lymphatic system cancer	0.00239	0.00529	CcSEcCtD
Fesoterodine—Diarrhoea—Teniposide—lymphatic system cancer	0.00237	0.00525	CcSEcCtD
Fesoterodine—Mediastinal disorder—Vincristine—lymphatic system cancer	0.00236	0.00523	CcSEcCtD
Fesoterodine—Chest pain—Bleomycin—lymphatic system cancer	0.00233	0.00516	CcSEcCtD
Fesoterodine—Back pain—Carmustine—lymphatic system cancer	0.00231	0.00512	CcSEcCtD
Fesoterodine—Mental disorder—Vincristine—lymphatic system cancer	0.00229	0.00508	CcSEcCtD
Fesoterodine—Confusional state—Bleomycin—lymphatic system cancer	0.00225	0.00499	CcSEcCtD
Fesoterodine—Vision blurred—Carmustine—lymphatic system cancer	0.00225	0.00498	CcSEcCtD
Fesoterodine—Hypersensitivity—Fludarabine—lymphatic system cancer	0.00224	0.00497	CcSEcCtD
Fesoterodine—Infection—Bleomycin—lymphatic system cancer	0.00222	0.00491	CcSEcCtD
Fesoterodine—Back pain—Vincristine—lymphatic system cancer	0.00221	0.00488	CcSEcCtD
Fesoterodine—Asthenia—Fludarabine—lymphatic system cancer	0.00218	0.00484	CcSEcCtD
Fesoterodine—Rash—Teniposide—lymphatic system cancer	0.00218	0.00484	CcSEcCtD
Fesoterodine—Dermatitis—Teniposide—lymphatic system cancer	0.00218	0.00483	CcSEcCtD
Fesoterodine—Dysgeusia—Mitoxantrone—lymphatic system cancer	0.00217	0.00481	CcSEcCtD
Fesoterodine—Headache—Teniposide—lymphatic system cancer	0.00217	0.00481	CcSEcCtD
Fesoterodine—Pruritus—Fludarabine—lymphatic system cancer	0.00215	0.00477	CcSEcCtD
Fesoterodine—Back pain—Mitoxantrone—lymphatic system cancer	0.00215	0.00476	CcSEcCtD
Fesoterodine—Vision blurred—Mitoxantrone—lymphatic system cancer	0.00209	0.00463	CcSEcCtD
Fesoterodine—Diarrhoea—Fludarabine—lymphatic system cancer	0.00208	0.00461	CcSEcCtD
Fesoterodine—Nausea—Teniposide—lymphatic system cancer	0.00206	0.00456	CcSEcCtD
Fesoterodine—Vertigo—Vincristine—lymphatic system cancer	0.00205	0.00454	CcSEcCtD
Fesoterodine—Chest pain—Carmustine—lymphatic system cancer	0.00203	0.0045	CcSEcCtD
Fesoterodine—Confusional state—Carmustine—lymphatic system cancer	0.00197	0.00435	CcSEcCtD
Fesoterodine—Cough—Mitoxantrone—lymphatic system cancer	0.00194	0.00429	CcSEcCtD
Fesoterodine—Infection—Carmustine—lymphatic system cancer	0.00194	0.00429	CcSEcCtD
Fesoterodine—Rash—Fludarabine—lymphatic system cancer	0.00192	0.00425	CcSEcCtD
Fesoterodine—Dermatitis—Fludarabine—lymphatic system cancer	0.00192	0.00425	CcSEcCtD
Fesoterodine—Headache—Fludarabine—lymphatic system cancer	0.00191	0.00422	CcSEcCtD
Fesoterodine—Tachycardia—Carmustine—lymphatic system cancer	0.0019	0.00421	CcSEcCtD
Fesoterodine—Chest pain—Mitoxantrone—lymphatic system cancer	0.00189	0.00419	CcSEcCtD
Fesoterodine—Infection—Vincristine—lymphatic system cancer	0.00185	0.00409	CcSEcCtD
Fesoterodine—Feeling abnormal—Bleomycin—lymphatic system cancer	0.00184	0.00407	CcSEcCtD
Fesoterodine—Confusional state—Mitoxantrone—lymphatic system cancer	0.00183	0.00405	CcSEcCtD
Fesoterodine—Nervous system disorder—Vincristine—lymphatic system cancer	0.00182	0.00404	CcSEcCtD
Fesoterodine—Nausea—Fludarabine—lymphatic system cancer	0.00181	0.00401	CcSEcCtD
Fesoterodine—Infection—Mitoxantrone—lymphatic system cancer	0.0018	0.00399	CcSEcCtD
Fesoterodine—Urticaria—Bleomycin—lymphatic system cancer	0.00177	0.00393	CcSEcCtD
Fesoterodine—Tachycardia—Mitoxantrone—lymphatic system cancer	0.00177	0.00392	CcSEcCtD
Fesoterodine—Insomnia—Carmustine—lymphatic system cancer	0.00176	0.0039	CcSEcCtD
Fesoterodine—Skin disorder—Mitoxantrone—lymphatic system cancer	0.00176	0.0039	CcSEcCtD
Fesoterodine—Somnolence—Carmustine—lymphatic system cancer	0.00173	0.00384	CcSEcCtD
Fesoterodine—Insomnia—Vincristine—lymphatic system cancer	0.00168	0.00373	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	0.00168	0.00373	CcSEcCtD
Fesoterodine—Constipation—Carmustine—lymphatic system cancer	0.00167	0.00369	CcSEcCtD
Fesoterodine—Hypersensitivity—Bleomycin—lymphatic system cancer	0.00165	0.00364	CcSEcCtD
Fesoterodine—Somnolence—Mitoxantrone—lymphatic system cancer	0.00161	0.00357	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	0.00161	0.00356	CcSEcCtD
Fesoterodine—Feeling abnormal—Carmustine—lymphatic system cancer	0.00161	0.00356	CcSEcCtD
Fesoterodine—Fatigue—Vincristine—lymphatic system cancer	0.0016	0.00355	CcSEcCtD
Fesoterodine—Asthenia—Bleomycin—lymphatic system cancer	0.0016	0.00355	CcSEcCtD
Fesoterodine—Dyspepsia—Mitoxantrone—lymphatic system cancer	0.00159	0.00353	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Carmustine—lymphatic system cancer	0.00159	0.00353	CcSEcCtD
Fesoterodine—Constipation—Vincristine—lymphatic system cancer	0.00159	0.00352	CcSEcCtD
Fesoterodine—Pruritus—Bleomycin—lymphatic system cancer	0.00158	0.0035	CcSEcCtD
Fesoterodine—Fatigue—Mitoxantrone—lymphatic system cancer	0.00156	0.00346	CcSEcCtD
Fesoterodine—Constipation—Mitoxantrone—lymphatic system cancer	0.00155	0.00343	CcSEcCtD
Fesoterodine—Abdominal pain—Carmustine—lymphatic system cancer	0.00154	0.00341	CcSEcCtD
Fesoterodine—Abdominal discomfort—Methotrexate—lymphatic system cancer	0.00152	0.00337	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Vincristine—lymphatic system cancer	0.00152	0.00337	CcSEcCtD
Fesoterodine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	0.00149	0.00331	CcSEcCtD
Fesoterodine—Dysuria—Methotrexate—lymphatic system cancer	0.00148	0.00329	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Mitoxantrone—lymphatic system cancer	0.00148	0.00328	CcSEcCtD
Fesoterodine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	0.00148	0.00327	CcSEcCtD
Fesoterodine—Abdominal pain—Vincristine—lymphatic system cancer	0.00147	0.00326	CcSEcCtD
Fesoterodine—Urticaria—Mitoxantrone—lymphatic system cancer	0.00144	0.00319	CcSEcCtD
Fesoterodine—Hypersensitivity—Carmustine—lymphatic system cancer	0.00144	0.00318	CcSEcCtD
Fesoterodine—Abdominal pain—Mitoxantrone—lymphatic system cancer	0.00143	0.00317	CcSEcCtD
Fesoterodine—Infestation—Methotrexate—lymphatic system cancer	0.00142	0.00313	CcSEcCtD
Fesoterodine—Infestation NOS—Methotrexate—lymphatic system cancer	0.00142	0.00313	CcSEcCtD
Fesoterodine—Rash—Bleomycin—lymphatic system cancer	0.00141	0.00312	CcSEcCtD
Fesoterodine—Dermatitis—Bleomycin—lymphatic system cancer	0.00141	0.00311	CcSEcCtD
Fesoterodine—Asthenia—Carmustine—lymphatic system cancer	0.0014	0.0031	CcSEcCtD
Fesoterodine—Hypersensitivity—Vincristine—lymphatic system cancer	0.00137	0.00304	CcSEcCtD
Fesoterodine—Hepatobiliary disease—Methotrexate—lymphatic system cancer	0.00134	0.00296	CcSEcCtD
Fesoterodine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	0.00133	0.00296	CcSEcCtD
Fesoterodine—Asthenia—Vincristine—lymphatic system cancer	0.00133	0.00296	CcSEcCtD
Fesoterodine—Diarrhoea—Carmustine—lymphatic system cancer	0.00133	0.00295	CcSEcCtD
Fesoterodine—Nausea—Bleomycin—lymphatic system cancer	0.00133	0.00294	CcSEcCtD
Fesoterodine—Asthenia—Mitoxantrone—lymphatic system cancer	0.0013	0.00288	CcSEcCtD
Fesoterodine—Dizziness—Carmustine—lymphatic system cancer	0.00129	0.00285	CcSEcCtD
Fesoterodine—Diarrhoea—Vincristine—lymphatic system cancer	0.00127	0.00282	CcSEcCtD
Fesoterodine—Urinary tract disorder—Methotrexate—lymphatic system cancer	0.00125	0.00278	CcSEcCtD
Fesoterodine—Urethral disorder—Methotrexate—lymphatic system cancer	0.00125	0.00276	CcSEcCtD
Fesoterodine—Diarrhoea—Mitoxantrone—lymphatic system cancer	0.00124	0.00275	CcSEcCtD
Fesoterodine—Dizziness—Vincristine—lymphatic system cancer	0.00123	0.00272	CcSEcCtD
Fesoterodine—Rash—Carmustine—lymphatic system cancer	0.00123	0.00272	CcSEcCtD
Fesoterodine—Dermatitis—Carmustine—lymphatic system cancer	0.00123	0.00272	CcSEcCtD
Fesoterodine—Headache—Carmustine—lymphatic system cancer	0.00122	0.0027	CcSEcCtD
Fesoterodine—Eye disorder—Methotrexate—lymphatic system cancer	0.00119	0.00263	CcSEcCtD
Fesoterodine—Cardiac disorder—Methotrexate—lymphatic system cancer	0.00118	0.00261	CcSEcCtD
Fesoterodine—Rash—Vincristine—lymphatic system cancer	0.00117	0.0026	CcSEcCtD
Fesoterodine—Dermatitis—Vincristine—lymphatic system cancer	0.00117	0.0026	CcSEcCtD
Fesoterodine—Headache—Vincristine—lymphatic system cancer	0.00117	0.00258	CcSEcCtD
Fesoterodine—Nausea—Carmustine—lymphatic system cancer	0.00116	0.00256	CcSEcCtD
Fesoterodine—Mediastinal disorder—Methotrexate—lymphatic system cancer	0.00115	0.00254	CcSEcCtD
Fesoterodine—Rash—Mitoxantrone—lymphatic system cancer	0.00114	0.00253	CcSEcCtD
Fesoterodine—Dermatitis—Mitoxantrone—lymphatic system cancer	0.00114	0.00253	CcSEcCtD
Fesoterodine—Headache—Mitoxantrone—lymphatic system cancer	0.00114	0.00251	CcSEcCtD
Fesoterodine—Mental disorder—Methotrexate—lymphatic system cancer	0.00111	0.00247	CcSEcCtD
Fesoterodine—Nausea—Vincristine—lymphatic system cancer	0.00111	0.00245	CcSEcCtD
Fesoterodine—Dysgeusia—Methotrexate—lymphatic system cancer	0.00108	0.0024	CcSEcCtD
Fesoterodine—Nausea—Mitoxantrone—lymphatic system cancer	0.00108	0.00238	CcSEcCtD
Fesoterodine—Back pain—Methotrexate—lymphatic system cancer	0.00107	0.00237	CcSEcCtD
Fesoterodine—Vision blurred—Methotrexate—lymphatic system cancer	0.00104	0.00231	CcSEcCtD
Fesoterodine—Vertigo—Methotrexate—lymphatic system cancer	0.000994	0.0022	CcSEcCtD
Fesoterodine—Cough—Methotrexate—lymphatic system cancer	0.000965	0.00214	CcSEcCtD
Fesoterodine—Chest pain—Methotrexate—lymphatic system cancer	0.000942	0.00209	CcSEcCtD
Fesoterodine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—lymphatic system cancer	0.000935	0.00207	CcSEcCtD
Fesoterodine—Confusional state—Methotrexate—lymphatic system cancer	0.00091	0.00202	CcSEcCtD
Fesoterodine—Infection—Methotrexate—lymphatic system cancer	0.000897	0.00199	CcSEcCtD
Fesoterodine—Nervous system disorder—Methotrexate—lymphatic system cancer	0.000885	0.00196	CcSEcCtD
Fesoterodine—Skin disorder—Methotrexate—lymphatic system cancer	0.000877	0.00194	CcSEcCtD
Fesoterodine—Insomnia—Methotrexate—lymphatic system cancer	0.000817	0.00181	CcSEcCtD
Fesoterodine—Somnolence—Methotrexate—lymphatic system cancer	0.000803	0.00178	CcSEcCtD
Fesoterodine—Dyspepsia—Methotrexate—lymphatic system cancer	0.000795	0.00176	CcSEcCtD
Fesoterodine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	0.000779	0.00173	CcSEcCtD
Fesoterodine—Fatigue—Methotrexate—lymphatic system cancer	0.000778	0.00172	CcSEcCtD
Fesoterodine—Feeling abnormal—Methotrexate—lymphatic system cancer	0.000744	0.00165	CcSEcCtD
Fesoterodine—Gastrointestinal pain—Methotrexate—lymphatic system cancer	0.000738	0.00163	CcSEcCtD
Fesoterodine—Urticaria—Methotrexate—lymphatic system cancer	0.000717	0.00159	CcSEcCtD
Fesoterodine—Abdominal pain—Methotrexate—lymphatic system cancer	0.000714	0.00158	CcSEcCtD
Fesoterodine—Hypersensitivity—Methotrexate—lymphatic system cancer	0.000665	0.00147	CcSEcCtD
Fesoterodine—Asthenia—Methotrexate—lymphatic system cancer	0.000648	0.00143	CcSEcCtD
Fesoterodine—Pruritus—Methotrexate—lymphatic system cancer	0.000639	0.00141	CcSEcCtD
Fesoterodine—Diarrhoea—Methotrexate—lymphatic system cancer	0.000618	0.00137	CcSEcCtD
Fesoterodine—Dizziness—Methotrexate—lymphatic system cancer	0.000597	0.00132	CcSEcCtD
Fesoterodine—Rash—Methotrexate—lymphatic system cancer	0.000569	0.00126	CcSEcCtD
Fesoterodine—Dermatitis—Methotrexate—lymphatic system cancer	0.000569	0.00126	CcSEcCtD
Fesoterodine—Headache—Methotrexate—lymphatic system cancer	0.000566	0.00125	CcSEcCtD
Fesoterodine—Nausea—Methotrexate—lymphatic system cancer	0.000536	0.00119	CcSEcCtD
